Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Amir Garakani, James W. Murrough, Rafael C. Freire, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 304
Sleep and anxiety: From mechanisms to interventions
Sarah L. Chellappa, Daniel Aeschbach
Sleep Medicine Reviews (2021) Vol. 61, pp. 101583-101583
Closed Access | Times Cited: 261
TGR5-mediated lateral hypothalamus-dCA3-dorsolateral septum circuit regulates depressive-like behavior in male mice
Xuyi Li, Shi-Ya Zhang, Yi-Zhou Hong, et al.
Neuron (2024) Vol. 112, Iss. 11, pp. 1795-1814.e10
Closed Access | Times Cited: 23
Anti‐neuroinflammation effects of transcutaneous auricular vagus nerve stimulation against depression‐like behaviors via hypothalamic α7nAchR/JAK2/STAT3/NF‐κB pathway in rats exposed to chronic unpredictable mild stress
Yu Chen, Yue Zhang, Junying Wang, et al.
CNS Neuroscience & Therapeutics (2023) Vol. 29, Iss. 9, pp. 2634-2644
Open Access | Times Cited: 32
Insomnia, anxiety and related disorders: a systematic review on clinical and therapeutic perspective with potential mechanisms underlying their complex link
Laura Palagini, Mario Miniati, Valerio Caruso, et al.
Neuroscience Applied (2024) Vol. 3, pp. 103936-103936
Open Access | Times Cited: 9
Sleep quality in eating disorders: A systematic review and meta-analysis
Giorgia Degasperi, Debora Meneo, Sara Curati, et al.
Sleep Medicine Reviews (2024) Vol. 77, pp. 101969-101969
Open Access | Times Cited: 9
Synthesis and Characterization of a New Carbon-11 Labeled Positron Emission Tomography Radiotracer for Orexin 2 Receptors Neuroimaging
Yanli Wang, Yongle Wang, Yan Liu, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 215-222
Open Access | Times Cited: 6
Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities
Matteo Carpi, Laura Palagini, Mariana Fernandes, et al.
Neuropharmacology (2023) Vol. 245, pp. 109815-109815
Open Access | Times Cited: 15
Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia
Andrew Hogyu Han, Caroline R. Burroughs, Evan P. Falgoust, et al.
Health psychology research (2023) Vol. 10, Iss. 5
Open Access | Times Cited: 13
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
The Black Book of Psychotropic Dosing and Monitoring.
Charles DeBattista, Alan F. Schatzberg
PubMed (2024) Vol. 54, Iss. 3, pp. 8-59
Closed Access | Times Cited: 5
Seltorexant for major depressive disorder
K.L. Valentino, Kayla M. Teopiz, Sabrina Wong, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
Stress-related neurodegenerative diseases: Molecular mechanisms implicated in neurodegeneration and therapeutic strategies
Maryam Azarfarin, Nasrollah Moradikor, Sara Salatin, et al.
Progress in brain research (2025)
Closed Access
Alzheimer’s disease with depression: clinical characteristics and potential mechanisms involving orexin and brain atrophy
Jing Li, Teng-hong Lian, Jinghui Li, et al.
Translational Psychiatry (2025) Vol. 15, Iss. 1
Open Access
Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents
Octavian Vasiliu
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 21
Acute orexin antagonism selectively modulates anticipatory anxiety in humans: implications for addiction and anxiety
Stephanie M. Gorka, Kia J. Khorrami, Charles A. Manzler, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 20
Orexin Receptor Antagonists and Insomnia
Xin Wu, Tao Xue, Zhouqing Chen, et al.
Current Psychiatry Reports (2022) Vol. 24, Iss. 10, pp. 509-521
Closed Access | Times Cited: 20
Unique Pharmacology, Brain Dysfunction, and Therapeutic Advancements for Fentanyl Misuse and Abuse
Ying Han, Lu Cao, Kai Yuan, et al.
Neuroscience Bulletin (2022) Vol. 38, Iss. 11, pp. 1365-1382
Open Access | Times Cited: 19
Exploring the mechanism of Suanzaoren decoction in treatment of insomnia based on network pharmacology and molecular docking
Shuxiao Wang, Zhao Yan, Xingang Hu
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 11
Rethinking the Role of Orexin in the Regulation of REM Sleep and Appetite
Maria P. Mogavero, Justyna Godos, Giuseppe Grosso, et al.
Nutrients (2023) Vol. 15, Iss. 17, pp. 3679-3679
Open Access | Times Cited: 11
Suvorexant for the prevention of delirium
Shu Xu, Yuanyuan Cui, Jinhua Shen, et al.
Medicine (2020) Vol. 99, Iss. 30, pp. e21043-e21043
Open Access | Times Cited: 29
The Periaqueductal Gray and Its Extended Participation in Drug Addiction Phenomena
Priscila Vázquez-León, Abraham Miranda-Páez, Jesús Chávez‐Reyes, et al.
Neuroscience Bulletin (2021) Vol. 37, Iss. 10, pp. 1493-1509
Open Access | Times Cited: 23
Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313
Priska Kaufmann, Marion Anliker‐Ort, Georg Golor, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 108, pp. 110166-110166
Closed Access | Times Cited: 24
Orexin receptor antagonists reverse aberrant dopamine neuron activity and related behaviors in a rodent model of stress-induced psychosis
Hannah B. Elam, Stephanie M. Perez, Jennifer J. Donegan, et al.
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 21
Dysregulation of striatal dopamine D2/D3 receptor-mediated by hypocretin induces depressive behaviors in rats
Bing Chen, Jiangang Xu, Simiao Chen, et al.
Journal of Affective Disorders (2023) Vol. 325, pp. 256-263
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top